Abstract
Every third cancer death in Israel is due to lung cancer. Still, 80% of the lung cancer cases are related to tobacco smoking; and therefore, more must be done for primary prevention, screening for lung cancer among risk cohort and against the tobacco industry. In the last decade, significant progress in the molecular understanding of this disease brought to a marked improvement in the overall survival and in the quality of life of these patients. The treatment paradigm is shifting from "one treatment fits all" regimens to personalized treatment strategies that allow patients to be treated with a variety of novel drugs that prolong their survival and maintain their quality of life. The latest revolutionary concept of immunotherapy in lung cancer is emerging and promises further hope to this population
Original language | English |
---|---|
Pages (from-to) | 510-1, 540 |
Journal | Harefuah |
Volume | 154 |
Issue number | 8 |
State | Published - 1 Aug 2015 |
ASJC Scopus subject areas
- General Medicine